Cian Healthcare Ltd Stock Price Today (NSE: CHCL)
Fundamental Score
Cian Healthcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Cian Healthcare Ltd share price today is ₹9.55, up +0.00% on NSE/BSE as of 7 August 2026. Cian Healthcare Ltd (CHCL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹23.88 (Cr). The 52-week high for CHCL share price is ₹73.03 and the 52-week low is ₹3.11. The company has a Return on Equity (ROE) of -49.19% and a debt-to-equity ratio of 3.36.
Cian Healthcare Ltd Share Price Chart — NSE/BSE Historical Performance
Cian Healthcare Ltd share price chart: 15.62% return over the past month. 52-week high ₹73.03, 52-week low ₹3.11.
Cian Healthcare Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) | |
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) | |
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) | |
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) | |
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) | |
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) | |
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) | |
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) | |
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) | |
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | 0.00 (Cr) |
Cian Healthcare Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹9.55 | ₹9.55 | ₹9.55 | ₹9.55 | +0.00% | |
| ₹8.26 | ₹9.55 | ₹8.26 | ₹9.55 | +15.62% | |
| ₹8.26 | ₹8.26 | ₹8.26 | ₹8.26 | +0.00% | |
| ₹8.26 | ₹8.26 | ₹8.26 | ₹8.26 | +0.00% | |
| ₹73.03 | ₹73.03 | ₹7.50 | ₹8.26 | -88.69% | |
| ₹73.03 | ₹73.03 | ₹73.03 | ₹73.03 | +0.00% | |
| ₹73.03 | ₹73.03 | ₹73.03 | ₹73.03 | +0.00% | |
| ₹5.58 | ₹73.03 | ₹4.74 | ₹73.03 | +1208.82% | |
| ₹5.84 | ₹5.84 | ₹4.72 | ₹5.48 | -6.16% | |
| ₹7.23 | ₹7.66 | ₹5.95 | ₹5.95 | -17.70% | |
| ₹5.04 | ₹7.09 | ₹4.94 | ₹7.09 | +40.67% | |
| ₹3.35 | ₹4.95 | ₹3.35 | ₹4.95 | +47.76% |
AI Research Briefing
Powered by Gemini · 2026-08-01
Insolvency turnaround with 95% promoter cornering but extreme balance sheet leverage makes this an uninvestable micro-cap risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major commercial order catalysts or material contracts disclosed in the last 4 weeks after live search. Regulatory disclosures show postal ballot outcome filing on July 10, 2026, and executive cessation filings on July 4, 2026. Earlier in Q1 2026, the company completed NCLT resolution implementation, securing trading approval for 2,50,00,000 equity shares following a ₹23.75 Cr promoter preferential allotment that expanded total share capital to ₹25.00 Cr.
CORE STORY (THE REAL GAME)
This is an insolvency turnaround play following CIRP resolution under new promoter Pradeep Kumar Jain and Ananta Medicare. The real game is not operational outperformance in contract manufacturing, but balance sheet restructuring and capital reduction following severe financial distress. Public float is compressed to 5% with promoters holding 95.0%.
- Post-NCLT trading approval granted for 2.5 Cr equity shares in Q1 2026.
- Postal ballot results filed on July 10, 2026, confirming governance updates post-restructuring.
- Extreme float compression with promoter group acquiring 67.89% incremental stake up to 95.0%.
- Inclusion of new commercial CDMO/CMO contracts with named order values.
- Debt resolution or deleveraging announcements from the new promoter group.
- Quarterly operational earnings turn to sustained positive operating income.
- Severe liquidity risk inherent to micro/SME caps with 95% promoter lock-in.
- Debt to Equity ratio at an unsustainable 3.36x with Interest Coverage of -43.91x.
- Negative profitability metrics with ROE at -49.19% and ROCE at -15.51%.
Promoters increased stake by 67.89% to 95.0% via NCLT resolution plan; institutional holding remains zero (0.0% FII, 0.0% DII).
Indian biopharma benefits from government SHAKTI initiative and PLI schemes, but micro-caps face severe working capital constraints.
No major order wins found after live search; primary news is ₹23.75 Cr preferential share issue under NCLT resolution.
Past cash generation visible with 5-year Free Cash Flow of ₹67.43 Cr, but current operating earnings remain deeply impaired.
Restructuring phase complete, but business execution depends entirely on capital infusion from new promoters over next 2-3 quarters.
Primary Thesis Risk
Inability to service heavy debt burden post-CIRP causing further equity dilution or operational halt.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Cian Healthcare Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Cian Healthcare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CHCL across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (37.58%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (42.69%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Cash Generation (₹67.43 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-49.19%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-15.51%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (-17.43% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Elevated Debt Levels (D/E: 3.36)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-43.91x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Public Float (95.00% Promoter Holding)
Observation: High promoter holding may restrict liquidity and price discovery.
Analysis: Very high promoter holding can limit trading liquidity.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Cian Healthcare Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Cian Healthcare Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Cian Healthcare LtdCian Healthcare...Selected✓ CHCL • 542678 | 28.1/100 | ₹9.55₹10 | ₹23.88₹23.88 | — — | -49.19%Poor -49.19% Poor | -15.51%Poor -15.51% Poor | 3.36Poor 3.4 Poor | — — | -17.43%Poor -17.43% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Cian Healthcare Ltd Quarterly Performance
Latest quarterly metrics for CHCL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
42.69%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
37.58%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-17.43%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Cian Healthcare Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CHCL — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Cian Healthcare Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Cian Healthcare Ltd (CHCL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Cian Healthcare Ltd
About CHCL (Cian Healthcare Ltd)
Cian Healthcare Ltd is a dynamic pharmaceutical company dedicated to improving lives through innovative healthcare solutions. Operating primarily in India, CHCL focuses on the enti...re lifecycle of drug development, from rigorous research and meticulous development to efficient manufacture and strategic marketing. The company prides itself on its commitment to quality and patient well-being, striving to provide accessible and affordable medications that address a wide spectrum of health needs. CHCL aims to be a trusted partner for healthcare professionals and patients alike, driven by a mission to enhance the quality of life through pharmaceutical excellence. CHCL's product portfolio reflects its comprehensive approach to healthcare, encompassing a diverse range of therapeutic areas. From specialized treatments in gynecology and critical cardio-diabetic medications to essential orthopedic and pediatric formulations, CHCL caters to the varied needs of a growing population. The company also recognizes the increasing importance of preventative care, offering a range of vitamins, nutrients, and dermacosmetic products designed to promote overall health and well-being. With a commitment to addressing evolving healthcare challenges, CHCL continuously expands its product offerings through active research and strategic collaborations. Beyond traditional pharmaceuticals, Cian Healthcare Ltd acknowledges and addresses specific unmet medical needs within the community. This proactive approach is exemplified through their commitment to providing specialized products in areas such as male and female infertility, contributing to reproductive wellness. Furthermore, the company recognizes the importance of cognitive health and offers products aimed at energy boosting and supporting individuals with autism. By focusing on these crucial areas, CHCL demonstrates a dedication to comprehensive healthcare and a commitment to improving the lives of individuals across diverse demographics and needs.
Company Details
Key Leadership
Latest News
CHCL Share Price: Frequently Asked Questions
What is the current share price of Cian Healthcare Ltd?
Cian Healthcare Ltd (CHCL) trades at ₹9.55 on NSE and BSE. Market cap ₹23.88 (Cr). Educational data only.
What is the P/E ratio of Cian Healthcare Ltd?
Cian Healthcare Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Cian Healthcare Ltd?
Cian Healthcare Ltd has a Bull Run score of 28.1/100 based on 25+ financial parameters.
Does Cian Healthcare Ltd pay dividends?
Cian Healthcare Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Cian Healthcare Ltd?
Cian Healthcare Ltd has ROE of -49.19%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Cian Healthcare Ltd?
Cian Healthcare Ltd has debt-to-equity of 3.36.
Is Cian Healthcare Ltd a good investment?
Bull Run gives Cian Healthcare Ltd a score of 28.1/100. This is not investment advice — consult a SEBI-registered advisor.